Leqembi & Kisunla: New Alzheimer's Treatments Explained | Dr. Armen J. Moughamian

Let's Talk Alzheimer's · Jun 11, 2026 · 34m

Just three years ago, there were no FDA-approved treatments that targeted the underlying causes of Alzheimer’s—only medications that modified symptoms. Today, two FDA-approved therapies—Leqembi (lecanemab) and Kisunla (donanemab)—clear amyloid protein from the brain, targeting a potential cause of the disease. Dr. Armen J. Moughamian, a neurologist and medical director of the Ray Dolby Brain Health Center at Sutter Health, joins this episode to answer common questions about what these new therapies can realistically do, including effectiveness, safety, eligibility, infusion logistics, cost…